Arrowhead Pharmaceuticals宣布启动其创新药物Aro-Dimer-Pa的一期/二期a阶段临床研究。该疗法作为全球首个双功能RNAi治疗药物，专门针对混合型高脂血症的临床需求而设计。
此次研究标志着RNAi疗法领域的重要突破。Aro-Dimer-Pa通过独特的双功能机制，有望为现有治疗方案提供新的选择。混合型高脂血症作为常见代谢性疾病，其治疗手段的革新将可能惠及广大患者群体。
临床研究的推进将重点评估该药物的安全性和初步疗效。随着试验的展开，医学界期待这一创新疗法能为血脂管理领域带来新的突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.